Cardiol Therapeutics Inc Class A
🇨🇦XTSE.CRDLCanadaHealthcare
PriceCA$2.23+0.18 (+8.78%)
Latest anomalies
Negative 2 detected in the last 120 days
- High: 1
- Medium: 2
- Low: 0
Asset turnover: declining while the industry median improves
Asset turnover: below the 10th percentile of its industry and country peers
PEG ratio: a sudden spike above its trailing quarter average
Free with a Finzer account.
Profile
- Healthcare
- Drug Manufacturers - Specialty & Generic
- Canada
Identity
- Exchange
- Toronto Stock Exchange . XTSE
- Type
- Stock
- ISIN
- CA14161Y2006
- CUSIP
- 14161Y200
Company
- Employees
- 18
- Headquarters
- Oakville, United States
- Website
- https://www.cardiolrx.com
Market
- Shares outstanding
- 121.5M
- Market cap
- CA$212.14M
Key dates
- Next earnings
- Nov 12, 2026
Highlights
- Market cap
- CA$212.14M
- EPS LTM
- -CA$0.45
- P/E LTM
- -3.02
- Div yield
- Not reported
Fundamentals (LTM)
- Revenue
- CA$00%unchanged year on year
- Net income
- -CA$37.55M-27.99%down year on year
- Gross margin
- Not reported
- Free cash flow
- -CA$25.1M-16.19%down year on year
Latest news
News is not sourced for this exchange.
Business summary
Cardiol Therapeutics Inc Class A is a company in the healthcare sector, listed on Toronto Stock Exchange (Canada) under the ticker CRDL. Its market capitalisation is CA$212.14M, from 121.5M shares outstanding, as of . Across the 141 trading sessions to the shares traded between CA$1.23 and CA$2.31, and the last close of CA$2.23 sits 93% of the way up that range. The company is headquartered in Oakville, United States, and employs about 18 people. The same company also trades as CRDL on Nasdaq.
Cardiol Therapeutics Inc., a clinical-stage life sciences company, focuses on the developing of anti-fibrotic and anti-inflammatory therapies for the treatment of heart diseases. Its lead product candidate is CardiolRx, which is in Phase III multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx in acute myocarditis, as well as for the treatment of recurrent pericarditis. The company is also developing CRD-38 injection for subcutaneous administration that is in preclinical development for the treatment of heart failure. It has a license agreement with Meros. The company was incorporated in 2017 and is headquartered in Oakville, Canada.